First-Line Chemotherapy With Capecitabine and Temozolomide in Patients With Metastatic Pancreatic Endocrine Carcinomas

By J. Strosberg, R. Fine, Junsung Choi, A. Nasir, D. Coppola, Dung-tsa Chen, James F. Helm, L. Kvols. Cancer, 2010

724 citations recorded by the source corpus.

Temozolomide is an active agent in metastatic pancreatic endocrine carcinomas. In vitro data indicate that the combination of capecitabine and temozolomide is synergistic for induction of apoptosis in neuroendocrine tumor cell lines. The authors retrospectively evaluated the efficacy of capecitabine and temozolomide in 30 patients with metastatic pancreatic endocrine carcinomas to assess response rate, progression free survival (PFS), and overall survival (OS).

Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Oncology

View Paper: https://www.semanticscholar.org/paper/812002231a52fc4d21075fa88b40b2a146b2d670

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. J. Zaknun
2. L. Bodei
3. Marianne Pavel
4. J. Mueller‐Brand
5. B. Oronsky
6. R. Baum
7. Dieter Hörsch
8. M. O'dorisio

Citations in the corpus

• The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours (2013, background): “Recent phase II studies have shown efficacy of temozolomide based chemotherapy either with antiangiogenic drugs or capecitabine [34, 35].”
• Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas (2017, background): “However, the combination with capecitabine demonstrated the most synergy in a 2011 study with a response rate of 70% and overall PFS of 18 months.(147) This synergy is schedule dependent, with best results observed when capecitabine precedes temozolomide, possibly due to partial depletion of levels ”